Global Intravenous Immunoglobulin Market: Snapshot

The global intravenous immunoglobulin market is gaining traction owing to rising prevalence of autoimmune disorders and increasing geriatric population. According to WHO, the global geriatric population is expected to rise from 524 mn in 2010 to 1.5 bn by the end of 2050. Weak immune system of geriatric population is one of the major factors responsible for the rise of the market. Rise in government initiatives to improve the infrastructure of healthcare sector in various emerging economies are favoring the global intravenous immunoglobulin market.

global intravenous immunoglobulin marketOther factors such as purification methods, advanced production technologies, and usage of off level indications are supplementing the rapid growth of market. These factors are providing potential opportunities to companies operating in the global intravenous immunoglobulin market. Off label indications are increasingly using intravenous immunoglobulin for treatment which is fueling the intravenous immunoglobulin products in the market.

Rapidly increasing neurological and hematological disorders such as myasthenia gravis, idiopathic thrombocytopenic purpura, and alloimmune thrombocytopenia are acting as chief factors driving the market. Neurological disorders is the prime factor for the market since, 40% of the world’s intravenous immunoglobulin products are used to treat these neurological diseases.

The global intravenous immunoglobulin market is expected to witness rising CAGR of 8.52% between 2017 and 2024. The global market was worth US$8,419.7 mn during 2017 and is anticipated to attain a valuation of US$14,923.2 mn by the end of 2024.

Global Intravenous Immunoglobulin Market Led by Primary Humoral Immunodeficiency Owing to Increased Autoimmune Disorders

The global intravenous immunoglobulin market according to indication is segmented into chronic lymphocytic leukemia, multifocal motor neuropathy (MMN), Kawasaki disease, guillain-barre syndrome, hypogammaglobulinemia, myasthenia gravis, primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). Among these, primary humoral immunodeficiency and chronic inflammatory polyneuropathy have been consuming more than half of the total demand in the market. While the latter segment is gaining popularity, the former segment is already driven by on label indication for intravenous immunoglobulin market. These two segments are anticipated to attain a valuation of US$4,145.4 mn and US$4,989.4 mn respectively by the end of 2024.

The global intravenous immunoglobulin market is also segmented according to end users into home caring settings, hospitals, and clinics.  Among these, hospitals are dominating the market by consuming 60% of the overall market during 2017. This segment is likely to lose its prominence to home care segment as demand for homecare segment has potentially risen in demand owing to technological advancement and development of products. 

Rise in Neurological Disorder to Boost Market in North America

The global intravenous immunoglobulin market is spread across regions such as Europe, North America, Latin America, Asia Pacific, and the Middle East & Africa. Among these, North America held valuation of US$3,814.8 during 2017. This region has the potential to generate more than 43.3% of the total demand in the market. The North America intravenous immunoglobulin market is majorly driven due to factors such as neurological disorders, increasing number of patient with blood disorder, advancement of technology, and ample amount of products available in this region.

Europe is expected to hold second position in the global intravenous immunoglobulin market but Asia Pacific is showing significant rise in the market. Asia pacific is expected to rise at a significant CAGR of 9.5% during the forecast period. Asia Pacific intravenous immunoglobulin market is anticipated to attain a valuation of US$2,826.1 mn by the end of 2024.

Some of the leading companies operating in the global intravenous immunoglobulin market are Baxalta Incorporated, Octapharma AG, Grifols S.A., and CSL Behring LLC.

Intravenous Immunoglobulin (IVIG) Market: Scope and Methodology

This report on the global intravenous immunoglobulin (IVIG) market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global intravenous immunoglobulin (IVIG) market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements. 

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the intravenous immunoglobulin (IVIG) market such as shift from intravenous to subcutaneous infusion of immunoglobulin. The key market indicators influencing global intravenous immunoglobulin (IVIG) market taken into consideration include prevalence of immunological disorders, global blood and plasma yield and geriatric population. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global intravenous immunoglobulin (IVIG) market. The report also highlights key events of the global intravenous immunoglobulin industry. A value chain analysis along with list of major players, hospitals and distributors is also included in the report.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2017 to 2024 are provided for all the segments, considering 2016 as the base year. The year on year growth of global intravenous immunoglobulin (IVIG) market for each segment is also reflected. Additionally, market related factors such as increasing preference for product innovation, and growing number of acute and chronic patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Intravenous Immunoglobulin (IVIG) Market: Segmentation

Based on indication, the global intravenous immunoglobulin (IVIG) market has been segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. Based on end-user, the market has been segmented into hospitals, clinics, and home care. Hospitals segment is expected to remain dominant during the forecast period. However, home care segment is expected to grow at a higher CAGR than others.

Geographically, the global intravenous immunoglobulin (IVIG) market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.

Intravenous Immunoglobulin (IVIG) Market: Competitive Landscape

The report also profiles major players in the intravenous immunoglobulin (IVIG) market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the intravenous immunoglobulin (IVIG) market is provided in the report. The report also includes a competition matrix that provides insights into recent developments and activities done by the major market players. Key companies profiled in the report include Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V.

The global intravenous immunoglobulin (IVIG) market has been segmented as follows:

Global Intravenous immunoglobulin (IVIG) Market, by Indication

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Primary Humoral Immunodeficiency
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Guillain-Barre Syndrome
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy (MMN)
  • Kawasaki Disease
  • Hypogammaglobulinemia
  • Chronic Lymphocytic Leukemia
  • Others

Global Intravenous immunoglobulin (IVIG) Market, by End-user

  • Hospitals
  • Clinics
  • Home Care

Global Intravenous immunoglobulin (IVIG) Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East & Africa
.